Disease-free survival (DFS) does not differ with adjuvant nivolumab plus ipilimumab (NIVO+IPI) compared with placebo in patients with localized renal cell carcinoma (RCC) at high risk for postnephrectomy relapse, according ...
Sep 14, 2022
0
9
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized phase 3 trial of neoadjuvant immunotherapy in patients with kidney cancer. Patients with high-risk renal ...
Sep 8, 2022
0
16
Kinase activity is frequently altered in renal cell carcinoma (RCC), and tyrosine kinase inhibitors (TKIs) are part of the standard treatment strategy in patients with metastatic disease. However, there are still no established ...
Aug 17, 2022
0
15
An international group of researchers investigated why mutations often associated with renal cancer result specifically in renal cancer, instead of other cancer types.
Aug 9, 2022
0
85
The formation of new blood vessels, also known as angiogenesis, is critical to the development and progression of cancer. Angiogenesis is controlled by many different protein messengers that can either stimulate or inhibit ...
Jul 8, 2022
0
13
Kidney cancer accounts for only 4% of all cancers in the United States; however, its incidence has more than doubled since 1975, with the most common type being clear cell renal cell carcinoma. While outcomes of patients ...
Jul 8, 2022
0
60
Chromophobe renal cell carcinoma (ChRCC) is a rare form of kidney cancer for which there are currently no proven treatments for metastatic or unresectable disease.
Jun 20, 2022
0
77
The tumor biomarker research team from the Suzhou Institute of Biomedical Engineering and Technology of the Chinese Academy of Sciences recently reported that DMDRMR/miR-378a-5p/ DAB2IP axis promotes angiogenesis and sunitinib ...
May 25, 2022
0
1
Investigators from UCLA Jonsson Comprehensive Cancer Center have identified a germline biomarker signature that successfully predicts which patients will suffer serious side effects that occur in up to 3 in ten patients on ...
Feb 3, 2022
0
29
A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors. ...
Jan 18, 2022
0
10
